Proliferative nodules in congenital melanocytic nevi

A clinicopathologic and immunohistochemical analysis

Mark D. Herron, Sheryll L. Vanderhooft, Kristi Smock, Holly Zhou, Sancy Leachman, Cheryl Coffin

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Congenital melanocytic nevi (CMN) occur in 1% to 2% of newborns, and the risk of malignant melanoma is increased in patients with large CMN. Appearance at birth or later of a nodular or hyperpigmented area within a CMN simulates malignant melanoma and prompts biopsy. Although their clinical and pathologic features seem ominous, proliferative nodules (PNs) typically are benign and may regress, although atypical features cause greater concern. Here we report clinical and pathologic findings with outcome in 10 children who had multiple biopsies of large CMN with PNs. We reviewed 78 separate samples from the 10 patients and classified the 60 PNs according to published criteria. A subset of 30 samples containing both the CMN and a PNs was analyzed for immunohistochemical reactivity for melanocytic (S-100 protein, HMB45, melan-A), lymphocytic (CD45), cell-cycle/proliferative (Mib-1, p16, p21, p27, c-Myc), apoptotic (p53, Bax, c-kit, CD95), and anti-apoptotic (bcl-2) markers. Both CMN and PNs had similar expression of melanocytic, lymphocytic, and most cell-cycle/proliferative and apoptotic markers, including Mib-1, p 16, p21, p27, c-Myc, Bax, CD95, and bcl-2. A greater proportion of PNs than CMN were reactive for p53 (67% vs. 30%, P <0.0098) and c-kit (97% vs. 3%, P <0.0001). p53 and p21 expression in CMN and all types of PNs were inversely correlated. When ordinary and atypical PNs were compared, the atypical PNs more frequently expressed p53, Mib-1, Bax, and bcl-2, but less frequently expressed p21. The c-kit expression in nearly all PNs and its absence in nearly all CMN is potentially useful for recognition of PN, suggests a delayed melanocytic maturation process in proliferative nodules, and may be likely indicative of their benign nature, p53 reactivity in concert with a lack of p21 up-regulation by immunohistochemistry suggests that a p53 mutation may be present in PN, although the immunohistochemical findings alone cannot exclude possible overexpression of wild-type p53. Regressive, involutional, or maturational changes were observed in sequential samples from 4 patients. No patient developed malignant melanoma or another melanocytic nevus-associated malignancy during the follow-up period. These findings underscore the similarities between PNs and the underlying CMN and suggest that maturational, proliferative, and apoptotic processes are involved in their clinical evolution.

Original languageEnglish (US)
Pages (from-to)1017-1025
Number of pages9
JournalAmerican Journal of Surgical Pathology
Volume28
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Pigmented Nevus
Melanoma
Cell Cycle
MART-1 Antigen
Biopsy
S100 Proteins
Up-Regulation
Immunohistochemistry
Parturition
Newborn Infant

Keywords

  • Congenital melanocytic nevus
  • Giant congenital nevus
  • Nodular melanocytic proliferation
  • Proliferative nodules
  • Pseudotumoral proliferative nodule

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Proliferative nodules in congenital melanocytic nevi : A clinicopathologic and immunohistochemical analysis. / Herron, Mark D.; Vanderhooft, Sheryll L.; Smock, Kristi; Zhou, Holly; Leachman, Sancy; Coffin, Cheryl.

In: American Journal of Surgical Pathology, Vol. 28, No. 8, 08.2004, p. 1017-1025.

Research output: Contribution to journalArticle

Herron, Mark D. ; Vanderhooft, Sheryll L. ; Smock, Kristi ; Zhou, Holly ; Leachman, Sancy ; Coffin, Cheryl. / Proliferative nodules in congenital melanocytic nevi : A clinicopathologic and immunohistochemical analysis. In: American Journal of Surgical Pathology. 2004 ; Vol. 28, No. 8. pp. 1017-1025.
@article{8c10eff1eacd49b7ab0eb16e88578ccb,
title = "Proliferative nodules in congenital melanocytic nevi: A clinicopathologic and immunohistochemical analysis",
abstract = "Congenital melanocytic nevi (CMN) occur in 1{\%} to 2{\%} of newborns, and the risk of malignant melanoma is increased in patients with large CMN. Appearance at birth or later of a nodular or hyperpigmented area within a CMN simulates malignant melanoma and prompts biopsy. Although their clinical and pathologic features seem ominous, proliferative nodules (PNs) typically are benign and may regress, although atypical features cause greater concern. Here we report clinical and pathologic findings with outcome in 10 children who had multiple biopsies of large CMN with PNs. We reviewed 78 separate samples from the 10 patients and classified the 60 PNs according to published criteria. A subset of 30 samples containing both the CMN and a PNs was analyzed for immunohistochemical reactivity for melanocytic (S-100 protein, HMB45, melan-A), lymphocytic (CD45), cell-cycle/proliferative (Mib-1, p16, p21, p27, c-Myc), apoptotic (p53, Bax, c-kit, CD95), and anti-apoptotic (bcl-2) markers. Both CMN and PNs had similar expression of melanocytic, lymphocytic, and most cell-cycle/proliferative and apoptotic markers, including Mib-1, p 16, p21, p27, c-Myc, Bax, CD95, and bcl-2. A greater proportion of PNs than CMN were reactive for p53 (67{\%} vs. 30{\%}, P <0.0098) and c-kit (97{\%} vs. 3{\%}, P <0.0001). p53 and p21 expression in CMN and all types of PNs were inversely correlated. When ordinary and atypical PNs were compared, the atypical PNs more frequently expressed p53, Mib-1, Bax, and bcl-2, but less frequently expressed p21. The c-kit expression in nearly all PNs and its absence in nearly all CMN is potentially useful for recognition of PN, suggests a delayed melanocytic maturation process in proliferative nodules, and may be likely indicative of their benign nature, p53 reactivity in concert with a lack of p21 up-regulation by immunohistochemistry suggests that a p53 mutation may be present in PN, although the immunohistochemical findings alone cannot exclude possible overexpression of wild-type p53. Regressive, involutional, or maturational changes were observed in sequential samples from 4 patients. No patient developed malignant melanoma or another melanocytic nevus-associated malignancy during the follow-up period. These findings underscore the similarities between PNs and the underlying CMN and suggest that maturational, proliferative, and apoptotic processes are involved in their clinical evolution.",
keywords = "Congenital melanocytic nevus, Giant congenital nevus, Nodular melanocytic proliferation, Proliferative nodules, Pseudotumoral proliferative nodule",
author = "Herron, {Mark D.} and Vanderhooft, {Sheryll L.} and Kristi Smock and Holly Zhou and Sancy Leachman and Cheryl Coffin",
year = "2004",
month = "8",
doi = "10.1097/01.pas.0000126785.61609.6e",
language = "English (US)",
volume = "28",
pages = "1017--1025",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Proliferative nodules in congenital melanocytic nevi

T2 - A clinicopathologic and immunohistochemical analysis

AU - Herron, Mark D.

AU - Vanderhooft, Sheryll L.

AU - Smock, Kristi

AU - Zhou, Holly

AU - Leachman, Sancy

AU - Coffin, Cheryl

PY - 2004/8

Y1 - 2004/8

N2 - Congenital melanocytic nevi (CMN) occur in 1% to 2% of newborns, and the risk of malignant melanoma is increased in patients with large CMN. Appearance at birth or later of a nodular or hyperpigmented area within a CMN simulates malignant melanoma and prompts biopsy. Although their clinical and pathologic features seem ominous, proliferative nodules (PNs) typically are benign and may regress, although atypical features cause greater concern. Here we report clinical and pathologic findings with outcome in 10 children who had multiple biopsies of large CMN with PNs. We reviewed 78 separate samples from the 10 patients and classified the 60 PNs according to published criteria. A subset of 30 samples containing both the CMN and a PNs was analyzed for immunohistochemical reactivity for melanocytic (S-100 protein, HMB45, melan-A), lymphocytic (CD45), cell-cycle/proliferative (Mib-1, p16, p21, p27, c-Myc), apoptotic (p53, Bax, c-kit, CD95), and anti-apoptotic (bcl-2) markers. Both CMN and PNs had similar expression of melanocytic, lymphocytic, and most cell-cycle/proliferative and apoptotic markers, including Mib-1, p 16, p21, p27, c-Myc, Bax, CD95, and bcl-2. A greater proportion of PNs than CMN were reactive for p53 (67% vs. 30%, P <0.0098) and c-kit (97% vs. 3%, P <0.0001). p53 and p21 expression in CMN and all types of PNs were inversely correlated. When ordinary and atypical PNs were compared, the atypical PNs more frequently expressed p53, Mib-1, Bax, and bcl-2, but less frequently expressed p21. The c-kit expression in nearly all PNs and its absence in nearly all CMN is potentially useful for recognition of PN, suggests a delayed melanocytic maturation process in proliferative nodules, and may be likely indicative of their benign nature, p53 reactivity in concert with a lack of p21 up-regulation by immunohistochemistry suggests that a p53 mutation may be present in PN, although the immunohistochemical findings alone cannot exclude possible overexpression of wild-type p53. Regressive, involutional, or maturational changes were observed in sequential samples from 4 patients. No patient developed malignant melanoma or another melanocytic nevus-associated malignancy during the follow-up period. These findings underscore the similarities between PNs and the underlying CMN and suggest that maturational, proliferative, and apoptotic processes are involved in their clinical evolution.

AB - Congenital melanocytic nevi (CMN) occur in 1% to 2% of newborns, and the risk of malignant melanoma is increased in patients with large CMN. Appearance at birth or later of a nodular or hyperpigmented area within a CMN simulates malignant melanoma and prompts biopsy. Although their clinical and pathologic features seem ominous, proliferative nodules (PNs) typically are benign and may regress, although atypical features cause greater concern. Here we report clinical and pathologic findings with outcome in 10 children who had multiple biopsies of large CMN with PNs. We reviewed 78 separate samples from the 10 patients and classified the 60 PNs according to published criteria. A subset of 30 samples containing both the CMN and a PNs was analyzed for immunohistochemical reactivity for melanocytic (S-100 protein, HMB45, melan-A), lymphocytic (CD45), cell-cycle/proliferative (Mib-1, p16, p21, p27, c-Myc), apoptotic (p53, Bax, c-kit, CD95), and anti-apoptotic (bcl-2) markers. Both CMN and PNs had similar expression of melanocytic, lymphocytic, and most cell-cycle/proliferative and apoptotic markers, including Mib-1, p 16, p21, p27, c-Myc, Bax, CD95, and bcl-2. A greater proportion of PNs than CMN were reactive for p53 (67% vs. 30%, P <0.0098) and c-kit (97% vs. 3%, P <0.0001). p53 and p21 expression in CMN and all types of PNs were inversely correlated. When ordinary and atypical PNs were compared, the atypical PNs more frequently expressed p53, Mib-1, Bax, and bcl-2, but less frequently expressed p21. The c-kit expression in nearly all PNs and its absence in nearly all CMN is potentially useful for recognition of PN, suggests a delayed melanocytic maturation process in proliferative nodules, and may be likely indicative of their benign nature, p53 reactivity in concert with a lack of p21 up-regulation by immunohistochemistry suggests that a p53 mutation may be present in PN, although the immunohistochemical findings alone cannot exclude possible overexpression of wild-type p53. Regressive, involutional, or maturational changes were observed in sequential samples from 4 patients. No patient developed malignant melanoma or another melanocytic nevus-associated malignancy during the follow-up period. These findings underscore the similarities between PNs and the underlying CMN and suggest that maturational, proliferative, and apoptotic processes are involved in their clinical evolution.

KW - Congenital melanocytic nevus

KW - Giant congenital nevus

KW - Nodular melanocytic proliferation

KW - Proliferative nodules

KW - Pseudotumoral proliferative nodule

UR - http://www.scopus.com/inward/record.url?scp=3242815178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242815178&partnerID=8YFLogxK

U2 - 10.1097/01.pas.0000126785.61609.6e

DO - 10.1097/01.pas.0000126785.61609.6e

M3 - Article

VL - 28

SP - 1017

EP - 1025

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 8

ER -